Objective of the study: to investigate the effect of meglumine succinate solution on the dynamics of metabolic blood parameters and respiratory function of the lungs in intensive care patients with new coronavirus infection. An observational prospective study included 105 patients with a severe course of novel coronavirus infection
Study Type
OBSERVATIONAL
Enrollment
105
the balanced succinate-containing crystalloid solution Reamberin (meglumine sodium succinate)
Ringer's solution at an average daily dose of 8.1 ml/kg/day
Nizhegorodskaya Regional Clinical Hospital named after N.A. Semashko
Nizhny Novgorod, Russia
Mortality, %
Proportion of patients died during the period of hospital stay
Time frame: from date of treatment start until the date of death or the date of discharge from hospital
Duration of treatment at ICU, days
Duration of treatment at ICU
Time frame: from date of treatment start until the date of death or the date of discharge from hospital
Duration of treatment after ICU, days
Duration of treatment after ICU
Time frame: from date of treatment start until the date of death or the date of discharge from hospital
Glucose
Venous blood Glucose
Time frame: baseline, day 2, day 3, day 5, day 11
Lactate
Venous blood Lactate
Time frame: baseline, day 2, day 3, day 5, day 11
pH
Blood gases
Time frame: baseline, day 2, day 3, day 5, day 11
BE
Blood gases
Time frame: baseline, day 2, day 3, day 5, day 11
Dynamics of right diaphragm excursion, cm
Diaphragm mobility
Time frame: baseline, day 2, day 3, day 5, day 11
Total duration of inpatient treatment, days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Total duration of inpatient treatment
Time frame: from date of treatment start until the date of death or the date of discharge from hospital